The company changed its name from Advanced Magnetics, Inc. to AMAG Pharmaceuticals, Inc. in July 2007.
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, developed and manufactured organ-specific diagnostic contrast agents that provide clearer images during magnetic resonance imaging (MRI) tests used to detect tumors and other abnormalities.
The company had two MRI related products on the market: Feridex I.V. (for the diagnosis of liver lesions) and GastroMARK (used for bowel and abdominal MR imaging). In November 2008, AMAG Pharmaceuticals, Inc. decided to discontinue the manufacturing of Feridex. The development of Combidex as a contrast agent for lymph disease has also been stopped.
The Company has now two commercial products: Feraheme® and GastroMARK®. Feraheme® is the trade name of Ferumoxytol (formerly Code 7228) and is indicated for the treatment of iron deficiency anemia. Feraheme® is also being developed as a diagnostic agent for vascular-enhanced magnetic resonance imaging (MRI) to assess peripheral arterial disease.

MRI Contrast Agents:

Founded in 1991, ImaRx Pharmaceutical Corp. designs, develops and markets pharmaceuticals for medical imaging (MRI, ultrasound and computed tomography) for the radiological imaging industry.
ImaRx Pharmaceutical Corp., announced 1999 that it has been acquired by E.I DuPont de Nemours and Co., Inc.. The terms of the acquisition provide a royalty-free licensing arrangement with a newly-formed company, ImaRx LLC ("LLC"), to pursue and develop new products and technologies for drug and gene delivery independent from DuPont. Yamanouchi Pharmaceutical Co. Ltd., ImaRx' licensee for Asian territories for this product, will continue to develop the product in Asia as DuPont's licensee. ImaRx LLC will have ownership of all other targeted and therapeutic products previously owned by ImaRx, including imaging products outside of diagnostic ultrasound imaging and two other imaging products, SonoRx® and LumenHance®, which are both FDA approved and licensed to BRACCO Diagnostics.

MRI Contrast Agents:

From GE Healthcare;
The Signa HDx MRI system is GE's leading edge whole body magnetic resonance scanner designed to support high resolution, high signal to noise ratio, and short scan times.
Signa HDx 3.0T offers new technologies like ultra-fast image reconstruction through the new XVRE recon engine, advancements in parallel imaging algorithms and the broadest range of premium applications. The HD applications, PROPELLER (high-quality brain imaging extremely resistant to motion artifacts), TRICKS (contrast-enhanced angiographic vascular lower leg imaging), VIBRANT (for breast MRI), LAVA (high resolution liver imaging with shorter breath holds and better organ coverage) and MR Echo (high-definition cardiac images in real time) offer unique capabilities.

From Siemens Medical Systems; Received FDA clearance in 2010.
MAGNETOM Skyra is a top-of-the-line, patient friendly wide bore 3 Tesla MRI system.
The system is equipped with the Tim 4G and Dot system (Total imaging matrix and Day optimizing throughput), to enhance both productivity and image quality with the complete range of advanced applications for clinical routine and research. Tim 4G features lighter, trimmer MRI coils that take up less space inside the magnet but deliver a high coil element density with increased signal to noise ratio and the possibility to use high iPAT factors.

From Toshiba America Medical Systems Inc.;
the Ultra™ system was developed to help healthcare providers be more competitive by delivering greater patient comfort and a broad range of clinical capabilities, says Anita Bowler, product manager, MRI Business Unit, Toshiba America Medical Systems Inc With its unique, powerful gradient technology, the Ultra™ performs advanced clinical studies and consistently provides high-resolution images that are typically associated with high field MRI systems. At the same time, the Ultra™ offers a truly open feeling that makes patients more relaxed, especially those with claustrophobic tendencies.